ART Advanced Research Technologies Inc.
TSX : ARA

ART Advanced Research Technologies Inc.

March 17, 2008 09:14 ET

ART Advanced Research Technologies to Be Present at the Annual Meeting of the Society of Toxicology in Seattle, WA

MONTREAL, CANADA--(Marketwire - March 17, 2008) - ART Advanced Research Technologies Inc. ("ART") (TSX:ARA), a Canadian medical device company and a leader in optical molecular imaging products for the healthcare and pharmaceutical industries, will be exhibiting at the Society of Toxicology (SOT) Annual Meeting, March 17-19, Seattle, WA. ART will showcase its preclinical product offering, including the Optix® MX2 optical imaging device and the Fenestra® line of contrast agents for micro CT imaging at its booth (#1639) located in the Exhibit Hall of the Washington State Convention and Trade Center. In addition, Dr. Joanna Napp from the University of Goettingen in Germany will be presenting recent research using the Optix device in a pancreatic tumor mouse model, to evaluate novel targeted tumor therapies by non-invasive time domain near infrared imaging.

The Society of Toxicology (SOT) Annual Meeting is the largest toxicology meeting and exhibition in the world, attracting approximately 6,200 scientists from industry, academia, and government. The program includes a plenary and other special lectures, symposia, workshops, roundtable discussions, and platform and poster presentations.

About ART

ART Advanced Research Technologies Inc. is a leader in molecular imaging products for the healthcare and pharmaceutical industries. ART has developed products in medical imaging, medical diagnostics, disease research, and drug discovery with the goal of bringing new and better treatments to patients faster. The Optix® optical molecular imaging system, designed for monitoring physiological changes in living systems at the preclinical study phases of new drugs, is used by industry and academic leaders worldwide. The SoftScan® optical medical imaging device is designed to improve the diagnosis and treatment of breast cancer. ART is commercializing these products in a global strategic alliance with GE Healthcare, a world leader in mammography and imaging. Finally, the Fenestra® line of molecular imaging contrast products provide image enhancement for a wide range of preclinical Micro CT applications allowing scientists to see greater detail in their imaging studies, with potential extension into other major imaging modalities. ART's shares are listed on the TSX under the ticker symbol ARA. For more information on ART, visit our website at www.art.ca .

This press release may contain forward-looking statements subject to risks and uncertainties that would cause actual events to differ materially from expectations. These risks and uncertainties are described in the most recent Annual Information Form and the financial statements for the year ended December 31, 2006, available on SEDAR (www.sedar.com).

Contact Information